Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: The clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in kidney transplant (KT) recipients is lower than in the general population.
METHODS: From April to October 2021, 481 KT recipients with COVID-19, included in the Spanish Society of Nephrology COVID-19 Registry, were analyzed. Data regarding vaccination status and vaccine type were collected, and outcomes of unvaccinated or partially vaccinated patients (n = 130) were compared with fully vaccinated patients (n = 351).
RESULTS: Clinical picture was similar and survival analysis showed no differences between groups: 21.7% of fully vaccinated patients and 20.8% of unvaccinated or partially vaccinated died (P = 0.776). In multivariable analysis, age and pneumonia were independent risk factors for death, whereas vaccination status was not related to mortality. These results remained similar when we excluded patients with partial vaccination, as well as when we analyzed exclusively hospitalized patients. Patients vaccinated with mRNA-1273 (n = 213) showed a significantly lower mortality than those who received the BNT162b2 vaccine (n = 121) (hazard ratio: 0.52; 95% confidence interval, 0.31-0.85; P = 0.010).
CONCLUSIONS: COVID-19 severity in KT patients has remained high and has not improved despite receiving 2 doses of the mRNA vaccine. The mRNA-1273 vaccine shows higher clinical effectiveness than BNT162b2 in KT recipients with breakthrough infections. Confirmation of these data will require further research taking into account the new variants and the administration of successive vaccine doses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
Transplantation - 106(2022), 7 vom: 01. Juli, Seite 1430-1439 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 24.06.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/TP.0000000000004119 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339146834 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339146834 | ||
| 003 | DE-627 | ||
| 005 | 20231227130742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TP.0000000000004119 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM339146834 | ||
| 035 | |a (NLM)35384924 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mazuecos, Auxiliadora |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in kidney transplant (KT) recipients is lower than in the general population | ||
| 520 | |a METHODS: From April to October 2021, 481 KT recipients with COVID-19, included in the Spanish Society of Nephrology COVID-19 Registry, were analyzed. Data regarding vaccination status and vaccine type were collected, and outcomes of unvaccinated or partially vaccinated patients (n = 130) were compared with fully vaccinated patients (n = 351) | ||
| 520 | |a RESULTS: Clinical picture was similar and survival analysis showed no differences between groups: 21.7% of fully vaccinated patients and 20.8% of unvaccinated or partially vaccinated died (P = 0.776). In multivariable analysis, age and pneumonia were independent risk factors for death, whereas vaccination status was not related to mortality. These results remained similar when we excluded patients with partial vaccination, as well as when we analyzed exclusively hospitalized patients. Patients vaccinated with mRNA-1273 (n = 213) showed a significantly lower mortality than those who received the BNT162b2 vaccine (n = 121) (hazard ratio: 0.52; 95% confidence interval, 0.31-0.85; P = 0.010) | ||
| 520 | |a CONCLUSIONS: COVID-19 severity in KT patients has remained high and has not improved despite receiving 2 doses of the mRNA vaccine. The mRNA-1273 vaccine shows higher clinical effectiveness than BNT162b2 in KT recipients with breakthrough infections. Confirmation of these data will require further research taking into account the new variants and the administration of successive vaccine doses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Villanego, Florentino |e verfasserin |4 aut | |
| 700 | 1 | |a Zarraga, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a López, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheimer, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Llinàs-Mallol, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Rivas, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Fuentes, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Toapanta, Néstor G |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello, Sheila |e verfasserin |4 aut | |
| 700 | 1 | |a Beneyto, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Aladrén, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Benot, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Canal, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, María |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Flores, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Saura, Isabel M |e verfasserin |4 aut | |
| 700 | 1 | |a Gavela, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Galeano, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Tabernero, Guadalupe |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Tamajón, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Moreno, Paloma L |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Girón, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Siverio, Orlando |e verfasserin |4 aut | |
| 700 | 1 | |a Labrador, Pedro J |e verfasserin |4 aut | |
| 700 | 1 | |a De Arriba, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Simal, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Cruzado, Leónidas |e verfasserin |4 aut | |
| 700 | 1 | |a Moina, Inigo |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalde, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Álvarez, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Marta |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Society of Nephrology COVID-19 Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation |d 1963 |g 106(2022), 7 vom: 01. Juli, Seite 1430-1439 |w (DE-627)NLM000023787 |x 1534-6080 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2022 |g number:7 |g day:01 |g month:07 |g pages:1430-1439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/TP.0000000000004119 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2022 |e 7 |b 01 |c 07 |h 1430-1439 | ||